Cyclo Therapeutics shares are trading higher after the company announced the presentation of preliminary data from its ongoing pivotal Phase 3 study and substudy evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1.
Portfolio Pulse from Benzinga Newsdesk
Cyclo Therapeutics shares rose following the announcement of preliminary data from its Phase 3 study on Trappsol Cyclo for Niemann-Pick Disease Type C1 treatment.
September 05, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cyclo Therapeutics shares increased after revealing preliminary data from its Phase 3 study on Trappsol Cyclo, a treatment for Niemann-Pick Disease Type C1.
The announcement of positive preliminary data from a pivotal Phase 3 study is a significant milestone for Cyclo Therapeutics, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100